Anti-IgE antibody therapy for Japanese cedar pollinosis: omalizumab update

Allergology International : Official Journal of the Japanese Society of Allergology
K Okubo, T Nagakura

Abstract

Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollens is a substantial problem in Japan. Omalizumab, a novel humanized monoclonal anti-immunoglobulin E (IgE) antibody, has already been proven to reduce symptoms associated with SAR. To investigate the safety and efficacy of omalizumab in the treatment of patients with Japanese cedar pollen-induced SAR compared to placebo or anti-allergic drug, two randomized, double-blind studies were conducted in Japan. Omalizumab (150, 225, 300, or 375 mg) or placebo was administered subcutaneously every 2 or 4 weeks based on serum total IgE and body weight at baseline. IPD was administered 300 mg per day through the season. Primary and all secondary efficacy variable scores were significantly lower in the omalizumab group than in the placebo group (P < .01) and IPD, Th2 cytokine inhibitor group (P < .01). Omalizumab was effective and safe in the treatment of SAR induced by Japanese cedar pollens. And the methods of increasing effects by combining omalizumab with antibody-specific immunotherapy are being considered. These strategy is more effective than immune-therapy alone.

References

Jul 1, 1997·The Journal of Allergy and Clinical Immunology·T B CasaleD C Adelman
Aug 10, 2000·The Journal of Allergy and Clinical Immunology·E AdelrothT Sandström
Nov 30, 2006·Allergology International : Official Journal of the Japanese Society of Allergology·Kimihiro OkuboTakeru Ishikawa
Jul 17, 2007·The Journal of Allergy and Clinical Immunology·Sven KlunkerUNKNOWN Immune Tolerance Network Group
Aug 8, 2007·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Matthias Volkmar KoppJoachim Kuehr
Sep 22, 2007·American Journal of Rhinology·Renee Penn, Suzette Mikula
Oct 2, 2007·The Journal of Allergy and Clinical Immunology·Ann C WuAnne L Fuhlbrigge
Dec 12, 2007·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·T NagakuraT Ishikawa
Jan 22, 2008·The Journal of Allergy and Clinical Immunology·Sonja A GrundmannRandolf Brehler
Apr 9, 2008·The Journal of Allergy and Clinical Immunology·Dennis RevickiPeter Dale

❮ Previous
Next ❯

Citations

Jan 1, 2010·Journal of Asthma and Allergy·Osmo Kari, K Matti Saari
Apr 30, 2013·Expert Opinion on Biological Therapy·Priyanka Vashisht, Thomas Casale
Jun 7, 2015·Clinical Reviews in Allergy & Immunology·David El-Qutob
Nov 23, 2012·Allergology International : Official Journal of the Japanese Society of Allergology·Chengbo YangYoshinori Mine
Jan 23, 2015·The Journal of Allergy and Clinical Immunology. in Practice·Jeffrey R Stokes, Thomas B Casale
Oct 7, 2017·Frontiers in Medicine·Jeffrey Stokes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.